Evidence map›Paper›PMID 34442372›Full record

ArticleJournal of personalized medicine2021

Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.

Samuel Alarie, Julie Hagan, Gratien Dalpé, Sina Faraji, Cynthia Mbuya-Bienge, Hermann Nabi, Nora Pashayan, Jennifer D Brooks, Michel Dorval, Jocelyne Chiquette and 15 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Samuel AlarieCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.
Julie HaganCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.ORCID 0000-0001-7647-5246
Gratien DalpéCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.
Sina FarajiCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.
Cynthia Mbuya-BiengeCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Hermann NabiCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Nora PashayanDepartment of Applied Health Research, Institute of Epidemiology and Healthcare, University College London, London WC1E 6BT, UK.
Jennifer D BrooksDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0001-7574-4256
Michel DorvalCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.ORCID 0000-0002-3207-8211
Jocelyne ChiquetteCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Laurence EloyQuébec Cancer Program, Ministère de la Santé et des Services Sociaux, Quebec City, QC G1S 2M1, Canada.
Annie TurgeonCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Laurence Lambert-CôtéCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Jean-Sébastien PaquetteDépartement de Médecine Familiale et de Médecine D'urgence, Université Laval, Quebec City, QC G1V 4G2, Canada.ORCID 0000-0002-9524-6761
Meghan J WalkerDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Julie LapointeCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Palmira Granados MorenoCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.ORCID 0000-0002-0501-9312
Kristina BlackmoreOntario Health (Cancer Care Ontario), Toronto, ON M5G 2L3, Canada.
Michael WolfsonSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Mireille BroedersRadboud Institute for Health Sciences, Radboud University Medical Center, 525 EZ Nijmegen, The Netherlands.
The Perspective I I Study Group
Bartha M KnoppersCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.
Anna M ChiarelliDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Jacques SimardCHU de Québec-Université Laval Research Center, Quebec City, QC G1V 4G2, Canada.
Yann JolyCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.

Funding

Genome Canada 13529
6 · The paper itself

Abstract

The success of risk-stratified approaches in improving population-based breast cancer screening programs depends in no small part on women's buy-in. Fear of genetic discrimination (GD) could be a potential barrier to genetic testing uptake as part of risk assessment. Thus, the objective of this study was twofold. First, to evaluate Canadian women's knowledge of the legislative context governing GD. Second, to assess their concerns about the possible use of breast cancer risk levels by insurance companies or employers. We use a cross-sectional survey of 4293 (age: 30-69) women, conducted in four Canadian provinces (Alberta, British Colombia, Ontario and Québec). Canadian women's knowledge of the regulatory framework for GD is relatively limited, with some gaps and misconceptions noted. About a third (34.7%) of the participants had a lot of concerns about the use of their health information by employers or insurers; another third had some concerns (31.9%), while 20% had no concerns. There is a need to further educate and inform the Canadian public about GD and the legal protections that exist to prevent it. Enhanced knowledge could facilitate the implementation and uptake of risk prediction informed by genetic factors, such as the risk-stratified approach to breast cancer screening that includes risk levels.

Indexed as

breast cancergenetic discriminationpopulation surveyrisk-stratified screeningwomen’s perspectives

Identifiers

PMID34442372
PMCPMC8398750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.